Related Experiment Video
Updated: Aug 18, 2025

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
Published on: September 22, 2020
Benefits of successful percutaneous coronary intervention in chronic total occlusion patients with diabetes
Shuai Zhao1, Yan Chen2, Qingyi Wang3
1Department of Cardiology, Xijing Hospital, The Fourth Military Medical University, 169 West Changle Road, Xi'an, 710032, Shaanxi, People's Republic of China.
Insights
Successful percutaneous coronary intervention (PCI) for chronic total occlusion (CTO) significantly improves outcomes and quality of life (QOL) for diabetic patients. These benefits are comparable to non-diabetic patients, indicating CTO-PCI is an effective strategy for all.
Area of Science:
- Cardiology
- Interventional Cardiology
- Diabetology
Background:
- Diabetes is common in patients with chronic total occlusion (CTO).
- Data on the impact of successful percutaneous coronary intervention (PCI) on clinical outcomes in diabetic CTO patients is controversial.
- No studies have compared quality of life (QOL) after CTO-PCI in diabetic versus non-diabetic patients.
Purpose of the Study:
- To evaluate the clinical outcomes and QOL after successful CTO-PCI in patients with and without diabetes.
- To identify risk predictors for clinical outcomes in diabetic patients undergoing successful CTO-PCI.
Main Methods:
- Prospective enrollment of consecutive patients undergoing elective CTO-PCI from April 2018 to May 2021.
- Patients were divided into Diabetes and No Diabetes groups.
- Collected data included baseline characteristics, symptoms, QOL, procedural details, complications, and 1-month and 1-year follow-up.
Main Results:
- A total of 1076 patients underwent CTO-PCI; 34.76% had diabetes and presented with more comorbidities and complex lesions.
- In-hospital and 1-year Major Adverse Cardiac Events (MACE) and all-cause mortality were similar between groups (p > 0.05).
- Number of lesions per patient was an independent risk factor for MACE and mortality (p < 0.001).
- Symptom severity and QOL significantly improved in both groups at 1 month and 1 year post-CTO-PCI, with similar improvements observed in diabetic patients.
Conclusions:
- Successful CTO-PCI is an effective strategy for improving clinical outcomes, symptoms, and QOL in CTO patients with diabetes.
- The positive impact of CTO-PCI on QOL is comparable between diabetic and non-diabetic patients.
- CTO-PCI offers significant benefits for diabetic patients, addressing a critical unmet need in cardiovascular care.
Background:
Diabetes was commonly seen in chronic total occlusion (CTO) patients but data regarding the impact of successful percutaneous coronary intervention (PCI) on clinical outcome of CTO patients with diabetes was controversial. And importantly, no studies have compared quality of life (QOL) after CTO-PCI in patients with and without diabetes.
Methods:
Consecutive patients undergoing elective CTO-PCI were prospectively enrolled from Apr. 2018 to May 2021. Patients were subdivided into 2 groups: Diabetes and No Diabetes. Detailed baseline characteristics, assessment of symptoms and QOL, angiographic and procedural details, in-hospital complications, and 1 month and 1 year follow-up data were collected. These data were analyzed accordingly for risk predictors of clinical outcome in patients who have diabetes and received successful CTO-PCI.
Results:
A total of 1076 patients underwent CTO-PCI attempts. Diabetes was present in 374 (34.76%) patients, who had more hypertension, previous PCI and stroke. Regarding the coronary lesions, diabetic patients suffered more LCX lesion, multivessel disease, number of lesions per patient, blunt stump, calcification and higher J-CTO score (p < 0.05). In-hospital major adverse cardiac event (MACE) (4.13% vs. 5.35%; p = 0.362) was similar in the two groups. At 1 month and 1 year follow-up after successful CTO-PCI, the incidence of MACE and all-cause mortality were also similar in the two groups (p > 0.05). Number of lesions per patient was an independent risk factor of MACE and all-cause mortality (p < 0.001) 1 year after successful CTO-PCI. Symptom and QOL were markedly improved regardless of diabetes both at 1 month and 1 year follow-up, and importantly, patients with diabetes showed similar degrees of improvement to those without diabetes (P > 0.05).
Conclusions:
Successful CTO-PCI could represent an effective strategy improving clinical outcome, symptoms and QOL in CTO patients with diabetes.
Related Concept Videos
Peripheral Artery Disease III: Interprofessional Care
Coronary Artery Disease V: Interprofessional Care
Acute Coronary Syndrome IV: Interprofessional Care
Peripheral Artery Disease V: Postoperative Nursing Management
Chronic Pancreatitis II: Collaborative Care
Assessment:
Peripheral Artery Disease IV: Nursing Management

